Last reviewed · How we verify
Measles, Mumps, Rubella vaccination
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens.
The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | Measles, Mumps, Rubella vaccination |
|---|---|
| Also known as | RVG 17654, BMR-NVI |
| Sponsor | N.M. Wulffraat |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly neutralize wild-type viruses upon future exposure, preventing infection or reducing disease severity.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (PHASE3)
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients (PHASE4)
- Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles, Mumps, Rubella vaccination CI brief — competitive landscape report
- Measles, Mumps, Rubella vaccination updates RSS · CI watch RSS
- N.M. Wulffraat portfolio CI